Righting the Script on Healthcare Ownership
Transforming Clinical Expertise from a Purchased Service into an Earned Stake
Do you remember buying your first home? You realized you would pay nearly twice the amount you borrowed, and the roof over your head transformed from a shelter into an investment you were determined to maximize.
As a renter, you aim to avoid damage marks during the exit inspection. An owner proactively prioritizes value creation, shifting from subsistence to improvement. Owners add window treatments to reduce electric costs, cultivate garden beds for curb appeal, and leave the faucets dripping on cold nights to protect unseen pipes.
Traditional healthcare VC engages clinical experts on a one-off basis, asking for feedback on one deal at a time from experts who don’t have a stake in the outcome. As a result, these experts have a “renters” mentality: to avoid damage, they may err on being overly academic or safe (i.e., hypercritical) in their assessment. Their compensation incentivizes uncovering flaws, and they lack both the influence and longevity to create opportunities on behalf of the investment.
Physicians Capital Fund (PhyCap) is different. It’s built on the “owner” mindset. Clinical experts comprise the fund’s DNA, the limited partner (LP) base: these LPs own the failures and directly benefit from the Fund’s successes. They aren’t just looking for reasons to say “no” but are actively thinking about how to clear or redesign hurdles into opportunities. An ad hoc consultant may tell you a window is drafty, but it’s up to the owner to apply the elbow grease to fix it. An LP’s commitment to reducing burn rates, cultivating customer leads, and building scalable infrastructure is rivaled by that of only the founder.
The Challenge: Exception-as-the-rule “Spectator” Capital
The healthcare and investment worlds have seen what happens when capital deployment is disconnected from clinical reality. Theranos raised nearly $1.3 billion over 12 years with a catastrophic outcome, siphoning capital away from promising technologies, largely because “spectators” in the boardroom couldn’t spot flaws in the lab.
Today, we face a similar systemic risk that limits our ability to translate the best healthcare solutions into clinical and community settings: geographic capital isolation. Seventy percent of healthcare innovation capital is sequestered in just three coastal hubs, representing only 10% of the US population. One state alone, California, sequestered nearly 50% of US VC in 2024. This physical distance between investment and deployment environments creates a geographical rift in the clinical perspectives that develop, deploy, and fund new healthcare technologies.
Nationally, the physician-to-patient ratio is 1:336 (1:213 in Massachusetts, home to capital hotspot Boston), but in rural environments, that ratio balloons 10x to ~1:3,000 and is accentuated by geography, with a 1:3,441 in the South and 1:1,979 in the Northeast. Additionally, 30% of rural hospitals are “vulnerable to closure” and 60% lack labor and delivery care. It isn’t difficult to imagine why a technology developed in a specialist-heavy Boston clinic may lack luster in a resource-constrained rural hospital. By relying on coastal SMEs, traditional VC ignores the “pebbles in the shoe’’ felt by the rest of the nation. Both technologies may be valuable, but their impact is not equal.
The Solution: Moving from SME-as-Consultant to SME-as-Owner
PhyCap operates from the conviction that geographical diversity and variety in clinical expertise codes DNA that translates into clinically functional solutions. While renters (i.e., one-off subject matter experts (SMEs)) look for problems; SME owners look for solutions.
PhyCap’s DNA is coded by LPs nationwide who represent expertise across the full healthcare value chain, including clinicians who grasp deployment realities, operators who understand scale, execs who make purchasing decisions, and manufacturers who recognize what’s actually buildable. This creates a capability continuum: just as DNA progresses through transcription and translation machinery before it’s folded into functional protein, the full-spectrum of PhyCap LP expertise orchestrates seamless support as a minimum viable product (MVP) scales to commercial production.
Below are a few examples of how PhyCap LPs partner with portfolio companies to facilitate product/market fit and widespread commercial adoption:
Beta Testing: Refining products in diverse, real-world clinical workflows.
Translation: Turning trendy tech into functional, easily adoptable instrumentation. This feature is especially important as AI becomes more pervasive, initiating a new reality to chart human and/or machine interactions in clinical environments.
Commercial Shortcuts: Anticipating fabrication challenges before mass production begins.
The SBIR/STTR Blueprint
The Small Business Innovation Research/Small Business Technology Transfer program (SBIR/STTR) has already proven the value of including clinical experts in investment decisions. The SBIR/STTR review process is rooted in rigorous SME input out of necessity. These early-stage, high-risk/high-reward technologies are fresh off the research bench and still enshrined in SME jargon.
A 2019 study of National Cancer Institute (NCI) SBIR/STTR investments showed that $787 million in funding (over ten years) generated:
53% of recipient companies generating revenue, totaling $9.1 billion in total sales
$26.1 Billion in total economic impact
11.6x Multiple on invested capital (MOIC) proxy (calculated as $9.1 B / $0.787 B)
While we cannot directly compare early-stage federal grants to early-stage venture capital, the contrast is clear: the NCI’s 11.6x MOIC proxy, compared with the 3x–5x MOIC typical of top-tier venture capital firms, emphasizes the positive impact of SME involvement.
Smart Thesis
Expertise is one half of PhyCap’s strategy. The other key component of PhyCap’s DNA is an investment thesis that enables the fund to bypass speculative “shiny objects” with long, uncertain return timelines and instead focus on practical, clinical solutions. By concentrating on Women’s Health and Health Inequity, Software as a Medical Device (SaMD), and Clinical Care Delivery Workflow Optimization, PhyCap targets top growth, high-utility segments of the $9.34 trillion global healthcare market.
The Fund’s prioritization of Women’s Health and Health Inequity (5.3% CAGR) is a strategic play for one of the largest healthcare segments (~50%) of a ~$5.5 trillion US market. SaMD (23.6% CAGR) enhances clinical decision-making without the astronomical “burn” of high-risk hardware. Combined, these two technology focus areas empower PhyCap to claim a piece of the anticipated $1 trillion shift (by 2035) from outdated administrative and infrastructure spending to AI-enabled personalized medicine. Through Clinical Care Delivery Workflow Optimization (16.6% CAGR), PhyCap prioritizes technologies that improve the day-to-day efficiency and effectiveness of medical practice, removing the “pebbles in the shoes’’ that contribute to provider burnout. When paired with the clinical LP network, these investment areas aren’t just smart; they serve our country’s future by unburdening clinical staff and increasing access to care that works where it’s deployed.
This pragmatic focus reflects PhyCap’s Midwest heritage and “Dust Bowl Mentality.” Shaped by historical periods of economic hardship (i.e., the Dust Bowl), the Midwest prioritizes grit, resilience, and resourcefulness, and PhyCap’s strategy reflects that commitment to enduring ingenuity. PhyCap prioritizes recession-resilient technologies that remain relevant regardless of the economic climate. In a recession, an expensive elective treatment takes second place to sustainability; a workflow solution that improves the bottom line and saves clinician time gains attractiveness.
The Neural Network of Healthcare’s Future
Clinical perspective must be integrated across the commercialization pathway, from inception, to development, to deployment. PhyCap offers clinical experts the opportunity to influence and own the future of healthcare by influencing both development and deployment. The Fund’s neural network comprises a diverse, geographically representative set of clinical experts committed to bringing transformational products to providers and patient communities nationwide. This clinic-first DNA encodes a fund that offers both capital and endorsement by a network of partners that will catapult portfolio companies to success.
WORK WITH PHYCAP FUND
Physicians Capital Fund invests $150K-$500K in Pre-Seed - Series A healthcare ventures focused on Clinical Care Delivery Workflow Optimization, Software as a Medical Device, and Women’s Health.
If you’re a physician or healthcare professional interested in getting involved, book an intro call with our team here.
If you’re a founder building a healthcare company, pitch us here.
Website: PhyCapFund.com
Email: info@46.capital
LinkedIn: Follow us on LinkedIn
X: Connect with us on X
DISCLOSURE
This message is for general informational purposes only. Information or materials presented in this message should not be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. This message does not provide specific investing advice or strategies to any individual. The investments and strategies discussed in the content may not be suitable for all investors and are not obligations of or guaranteed by FortySix Capital or any of its affiliates. Nothing contained in this message constitutes investment, legal, tax, or other advice, nor is it to be relied on in making an investment or other decision. Past performance is not indicative of future results. The securities are being offered in reliance on an exemption from the registration requirements (Regulation D 506c), and therefore are not required to comply with certain specific disclosure requirements. The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.